The Novartis Institute for Tropical Diseases (NITD) is collaborating with the Genomics Institute of the Novartis Research Foundation, Swiss Tropical and Public Health Institute, and Scripps Research Institute to discover and develop new antimalarial compounds that target both Plasmodium falciparum and Plasmodium vivax.
The NITD and its partners are developing a potential one-dose cure for Plasmodium falciparum, and a curative modality for Plasmodium vivax. Two compounds resulting from these drug discovery efforts are currently in Phase II clinical trials, KAE609 and KAF156.
In November 2013, Novartis and collaborators announced the discovery of yet another new malaria drug target and a new compound class with potential to prevent, block and treat malaria. Called imidazopyrazines, this is the third new class of malaria compounds discovered by Novartis scientists within the last five years.
|Location||East Asia and Pacific, United States, Thailand|
|Value||USD 20 Million|